Compare Barclays PLC (BCS) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Barclays PLC vs 22nd Century Group Inc — how do they compare? Barclays PLC trades at $28.26 (market cap $94.48B), while 22nd Century Group Inc trades at $4.21 (market cap $1.49M). The key difference: Barclays PLC is far larger — about 63409.4× 22nd Century Group Inc's market cap, and Barclays PLC pays a 2.18% dividend while 22nd Century Group Inc pays none. Which is the better fit depends on your goals.
| BCS | XXII | |
|---|---|---|
Market Cap | $94.48B | $1.49M |
Sector | Financials | Technology |
52-Week High | $28.56 | $801.00 |
52-Week Low | $19.36 | $3.72 |
Dividend Yield | 2.18% | — |
Enterprise Value | — | -$6.74M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Barclays PLC (BCS) trades at $28.09, up 0.39% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows a low P/E of 10.68 and P/B of 0.88, indicating potential undervaluation. Revenue grew to $29.14B in 2025, with net income margin at 25.51%, though cash flow volatility from 2023-2024 remains a concern. Recent news highlights a securities investigation and mixed analyst views post-Q2 results.
Outlook is cautiously optimistic due to valuation appeal and earnings strength, but risks include legal scrutiny and cost pressures. Analyst consensus is 68% buy, with sentiment tempered by near-term headwinds. The stock offers value if operational efficiency improves, yet investors should monitor the class-action probe and expense trends.
22nd Century Group (XXII) trades at $4.31, down 0.92% on the day, with a neutral technical signal and bearish moving averages. The company shows deep unprofitability with a gross margin of -52.19% and net margin of -65.76%, though revenue was $7.05M in 2025. Recent corporate actions include a 20:1 reverse stock split in June 2026, and news highlights retail expansion for VLN reduced-nicotine cigarettes in California and New York.
The outlook remains speculative with high execution risk amid persistent losses, but analyst sentiment is bullish with 75% buy ratings. Key risks include negative cash flow from operations, regulatory hurdles for tobacco products, and the need for successful commercialization of VLN to achieve profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Barclays PLC
Barclays is a universal bank headquartered in the United Kingdom. It operates via two principal segments
Read more on BCS →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
